TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23782653

Group type: EXPERIMENTAL
Intervention: Home-based task-specific reach-to-grasp (RTG) training, 14 training sessions, each 1 hour long, over 6 weeks, with encouragement for 1 hour/day independent practice (total of 56 hours).
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care arm therapy.
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Home-based task-specific reach-to-grasp (RTG) training
Number of subjects: 50

Group type: COMPARATOR
Intervention: Usual care arm therapy
Number of subjects: 50
Study: 21958767

Group type: EXPERIMENTAL
Intervention: Fibrin sealant (FS)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Standard lung closure
Number of subjects: 185
Study: 18245179

Group type: EXPERIMENTAL
Intervention: olanzapine plus metformin (15 mg/day + 750 mg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: olanzapine plus placebo (15 mg/day + placebo)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: olanzapine plus metformin
Number of subjects: 40

Group type: COMPARATOR
Intervention: olanzapine plus placebo
Number of subjects: 40
Study: 16178291

Group type: EXPERIMENTAL
Intervention: Allevyn Adhesive
Number of subjects: 32

Group type: COMPARATOR
Intervention: Biatain Adhesive
Number of subjects: 32
Study: 12682319

Group type: EXPERIMENTAL
Intervention: Risperidone (mean daily dose of 2.5 +/- 0.85)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Risperidone (in children)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo (in children)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 34
Study: 10637197

Group type: EXPERIMENTAL
Intervention: TMP grade 3
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: TMP grade 2
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: TMP grades 0 and 1
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: TMP grades 0 or 1
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Corrected TIMI frame count
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Presence of anterior myocardial infarction
Number of subjects: 762

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 762
Study: 8969678

Group type: EXPERIMENTAL
Intervention: Concurrent administration of prostaglandin analogues to support gastric homeostasis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Development or identification of an NSAID that targets inflammatory prostaglandins while sparing homeostatic ones
Number of subjects: 0
Study: 1643676

Group type: EXPERIMENTAL
Intervention: Midazolam 0.5 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 0.75 mg.kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Midazolam 1.0 mg.kg‐1
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 6442057

Group type: EXPERIMENTAL
Intervention: Auranofin (oral gold salt)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sodium aurothiomalate (parenteral gold salt)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other baseline antirheumatoids (D-penicillamine, antimalarials)
Number of subjects: 0
Study: 31978611

Group type: EXPERIMENTAL
Intervention: Intravenous ribavirin for confirmed LF patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Standardized supportive care and biological monitoring
Number of subjects: 150
Study: 31171878

Group type: EXPERIMENTAL
Intervention: Triplet therapy (dabrafenib, trametinib, pembrolizumab)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Doublet therapy (dabrafenib, trametinib, placebo)
Number of subjects: 120
Study: 29162875

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AEx)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Diet (Diet)
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Exercise plus diet (AED)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No-intervention (NI)
Number of subjects: 115
Study: 25716883

Group type: EXPERIMENTAL
Intervention: Percutaneous Kirschner-wire fixation
Number of subjects: 461

Group type: COMPARATOR
Intervention: Volar locking-plate fixation
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Kirschner-wire fixation
Number of subjects: 461

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 461
Study: 24628035

Group type: COMPARATOR
Intervention: TA-8995 (5, 10, 25, 50, 100, 150 mg single doses; 1, 2.5, 10, 25 mg once daily for 21-28 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: TA-8995 (2.5 to 25 mg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21887500

Group type: EXPERIMENTAL
Intervention: OFD + rhGDF‐5/β‐TCP
Number of subjects: 20

Group type: COMPARATOR
Intervention: OFD alone (control)
Number of subjects: 20
Study: 19200119

Group type: EXPERIMENTAL
Intervention: 1.5% conjugated linoleic acid (CLA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate (PHO)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5% salt (SAL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 0.5% salt (SPH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 1.5% CLA (PCL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.5% salt, 1.5% CLA (SCL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.4% sodium tripolyphosphate, 0.5% salt, 1.5% CLA (SPC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CLA (inclusion in fresh steaks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CLA (inclusion in cooked steaks)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Treatment x day interactions
Number of subjects: 24
Study: 17539715

Group type: EXPERIMENTAL
Intervention: Crown-lengthening surgery (CLS)
Number of subjects: 19
Study: 15242422

Group type: EXPERIMENTAL
Intervention: [(18)F]fluoro‐2‐deoxy‐d‐glucose (FDG) positron emission tomography
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 31
Study: 11098982

Group type: EXPERIMENTAL
Intervention: Ciaglia PDT kit
Number of subjects: 100

Group type: COMPARATOR
Intervention: Griggs PDT kit
Number of subjects: 100
Study: 9298173

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 8145485

Group type: EXPERIMENTAL
Intervention: Silicone IOLs
Number of subjects: 125

Group type: COMPARATOR
Intervention: PMMA IOLs
Number of subjects: 125
Study: 3533567

Group type: EXPERIMENTAL
Intervention: 5 mg capsules of nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg capsules of nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg capsules of nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg tablets of nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: All doses of nifedipine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg and 20 mg capsules and 20 mg tablets
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine tablets
Number of subjects: 12
Study: 31778632

Group type: EXPERIMENTAL
Intervention: Furosemide (40 mg IV)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Acetazolamide (500 mg IV)
Number of subjects: 26
Study: 28420629

Group type: EXPERIMENTAL
Intervention: Dexamethasone (8 mg intravenous at induction of anaesthesia)
Number of subjects: 1350

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1350
Study: 25606834

Group type: EXPERIMENTAL
Intervention: Active laser treatment (5 mV, 650 nm, 20 minutes a day, 5 days a week for 4 weeks)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Inactive dummy treatment (placebo)
Number of subjects: 66
Study: 24307207

Group type: EXPERIMENTAL
Intervention: zuclopenthixol at a dose of 2-20 mg/d
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 20884014

Group type: EXPERIMENTAL
Intervention: Minor clinical impairment RRMS patients (n=33)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Major clinical impairment RRMS patients (n=25)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Healthy controls (n=40)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: RRMS patients (minor and major)
Number of subjects: 98
Study: 19405040

Group type: EXPERIMENTAL
Intervention: Glucaffect
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study: 17317388

Group type: EXPERIMENTAL
Intervention: Dry Eye Syndrome (DES)
Number of subjects: 690
Study: 15220318

Group type: EXPERIMENTAL
Intervention: Normoxia (inspired O(2) fraction = 0.21)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Hypoxia (inspired O(2) fraction = 0.14)
Number of subjects: 10
Study: 11598604

Group type: EXPERIMENTAL
Intervention: hGH treatment (28 IU/m2/wk)
Number of subjects: 481
Study: 10401821

Group type: EXPERIMENTAL
Intervention: Toupet fundoplication (TF)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Nissen fundoplication (NF)
Number of subjects: 256
Study: 7575274

Group type: EXPERIMENTAL
Intervention: Decapinol mouthwash 2 mg/mL
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 2105988

Group type: EXPERIMENTAL
Intervention: Prostacyclin (PGI2) administration
Number of subjects: 270

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study: 6157203

Group type: EXPERIMENTAL
Intervention: Econazole nitrate 150 mg per day for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Econazole nitrate 50 mg per day for 14 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Econazole nitrate (both regimens)
Number of subjects: 0
Study: 30152573

Group type: EXPERIMENTAL
Intervention: Intranasal OXT (24 IU)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Partner support (handholding)
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (unfamiliar person support)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Neural response to shocks
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Functional coupling between AI and MFG
Number of subjects: 194
Study: 27791246

Group type: EXPERIMENTAL
Intervention: 1.4 mm with biaxial microincision phacoemulsification (25 eyes)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.2 mm with coaxial phacoemulsification (62 eyes)
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1.8 mm with coaxial phacoemulsification (27 eyes)
Number of subjects: 90
Study: 25547068

Group type: EXPERIMENTAL
Intervention: Trained group (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-Trained group (n = 11)
Number of subjects: 21
Study: 23955709

Group type: EXPERIMENTAL
Intervention: 25,000 IU retinyl palmitate capsule daily for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsule daily for 6 months
Number of subjects: 0
Study: 21828156

Group type: EXPERIMENTAL
Intervention: Music (Mozart's Sonata for Two Pianos in D Major)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Headphones (noise-cancellation headphones, no music)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 19216763

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT) consisting of mobilisations, exercise therapy for the cervical and thoracic spine, and postural correction.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP) according to national Dutch general practice guidelines for headache.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Manual therapy (MT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care by the general practitioner (GP)
Number of subjects: 0
Study: 17646620

Group type: EXPERIMENTAL
Intervention: Rivastigmine patches
Number of subjects: 1059
Study: 12927313

Group type: EXPERIMENTAL
Intervention: Tibolone (2.5 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Calcium carbonate (1 tab/day, placebo)
Number of subjects: 64
Study: 11004055

Group type: EXPERIMENTAL
Intervention: Local dermatomal stimulation
Number of subjects: 68

Group type: COMPARATOR
Intervention: Needles only
Number of subjects: 68

Group type: COMPARATOR
Intervention: Remote dermatomal stimulation
Number of subjects: 68
Study: 9000318

Group type: EXPERIMENTAL
Intervention: Neuroleptic treatment (traditional antipsychotic drugs)
Number of subjects: 44
Study: 1361435

Group type: EXPERIMENTAL
Intervention: Alfuzosin (alpha 1-receptor-blocking compound)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 6437263

Group type: EXPERIMENTAL
Intervention: 5 mg D2343
Number of subjects: 8

Group type: COMPARATOR
Intervention: 5 mg terbutaline
Number of subjects: 8
Study: 3723158

Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous propranolol
Number of subjects: 0
Study: 29493361

Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS) for glucose prediction during hypoglycemia or hyperglycemia events
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control phase (CP) where patients followed decisions without knowing the glucose prediction
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Usability of the DSS
Number of subjects: 12
Study: 27291982

Group type: EXPERIMENTAL
Intervention: Home-based training program for caregivers of AD patients
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Home-based training program for caregivers of VaD patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group for caregivers of AD patients
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group for caregivers of VaD patients
Number of subjects: 114
Study: 24560278

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10mg/day for 4 months
Number of subjects: 54

Group type: COMPARATOR
Intervention: Zinc supplementation 30mg/day
Number of subjects: 54
Study: 22527372

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional Coronary Angiography (CCA)
Number of subjects: 56
Study: 20237029

Group type: EXPERIMENTAL
Intervention: Vitamin C (100 mg every 4 h for 6 days)
Number of subjects: 72
Study: 19000845

Group type: EXPERIMENTAL
Intervention: Computerized educational session and provision of 200 folate tablets
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 446
Study: 15992223

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.15 mg/kg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 90
Study: 14634409

Group type: EXPERIMENTAL
Intervention: Sildenafil citrate (50 mg, adjustable to 100 or 25 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 10995004

Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (9CRA) at 60 mg/m2 daily for 1 week, then escalating to 100 mg/m2 during the second week, up to a maximum of 140 mg/m2 for a planned duration of 48 weeks.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 9-cis retinoic acid (9CRA)
Number of subjects: 30
Study: 8626872

Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 1469177

Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract (SDD) with Cefotaxime i.v. (6 g/day) for the first four days and Polymyxin E, Tobramycin and Amphotericin B at the oropharyngeal and gastrointestinal level throughout the whole stay
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Selective Decontamination of the Digestive Tract (SDD)
Number of subjects: 101
Study: 6378145

Group type: EXPERIMENTAL
Intervention: One knife
Number of subjects: 586

Group type: COMPARATOR
Intervention: Two knives
Number of subjects: 586
Study: 30101278

Group type: EXPERIMENTAL
Intervention: Intravenous fentanyl
Number of subjects: 0

Group type: COMPARATOR
Intervention: Morphine (Control)
Number of subjects: 0
Study: 29540661

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 900 mg/day for 7 days before surgery
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no N-acetylcysteine)
Number of subjects: 70
Study: 26963952

Group type: EXPERIMENTAL
Intervention: Older men with age-related low T levels (4% positive for antipituitary antibodies)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Healthy young and older eugonadal men (0% positive for antipituitary antibodies)
Number of subjects: 182
Study: 24687829

Group type: EXPERIMENTAL
Intervention: Bevacizumab-containing therapy (BEV-CT)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Chemotherapy alone (CT)
Number of subjects: 361
Study: 22574084

Group type: EXPERIMENTAL
Intervention: Personalized iron supplementation program (B group)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Control group with free iron tablets (A group)
Number of subjects: 360
Study: 20565514

Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg daily) plus counselling
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 17553747

Group type: EXPERIMENTAL
Intervention: Verbal information delivery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Written information delivery
Number of subjects: 99

Group type: COMPARATOR
Intervention: Audiovisual information delivery
Number of subjects: 99
Study: 16200253

Group type: EXPERIMENTAL
Intervention: Vitamin C (5 g/day for 28 days)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 12857697

Group type: EXPERIMENTAL
Intervention: One-on-one interviews with faculty
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Critical incident report (CIR) followed by one-on-one interview
Number of subjects: 68

Group type: COMPARATOR
Intervention: One-on-one interviews with no CIR
Number of subjects: 68

Group type: COMPARATOR
Intervention: Critical incident report (CIR)
Number of subjects: 68
Study: 10758459

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study: 8987965

Group type: EXPERIMENTAL
Intervention: Five-day walking group (n = 17)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Three-day walking group (n = 19)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Sedentary control group (n = 20)
Number of subjects: 56
Study: 1290634

Group type: EXPERIMENTAL
Intervention: Disodium pamidronate (APD) administered as a single i.v. infusion of 30, 60 or 90 mg depending on serum calcium.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Mithramycin given in doses of 1.25 mg, repeated if necessary within the first three days.
Number of subjects: 25
Study: 3937509

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg tablets, 1 tablet twice daily)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Indapamide (2.5 mg tablets, 1 tablet every morning)
Number of subjects: 59
Study: 30785667

Group type: EXPERIMENTAL
Intervention: Gastrografin (GG)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laxative bowel preparation (LBP)
Number of subjects: 120
Study: 30045006

Group type: EXPERIMENTAL
Intervention: Melatonin (3 mg in the morning and 5 mg at bedtime for 12 months)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (2 x 1 tablet for 12 months)
Number of subjects: 60
Study: 26223511

Group type: EXPERIMENTAL
Intervention: Written Emotional Disclosure (WED)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Neutral writing task (Control)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of emotional content
Number of subjects: 24
Study: 24675168

Group type: EXPERIMENTAL
Intervention: L6 diet (average n‐3, low n‐6)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H3-L6 diet (high n‐3, low n‐6 LA)
Number of subjects: 0
Study: 22585767

Group type: EXPERIMENTAL
Intervention: suma/nap 10/60 mg
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: suma/nap 30/180 mg
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: suma/nap 85/500 mg
Number of subjects: 490

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 490
Study: 19892351

Group type: EXPERIMENTAL
Intervention: Low fat diet plus 40 mg/day of pravastatin
Number of subjects: 180

Group type: COMPARATOR
Intervention: Low fat diet
Number of subjects: 180
Study: 18697875

Group type: COMPARATOR
Intervention: GH replacement
Number of subjects: 268
Study: 16038474

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 1077
Study: 12208704

Group type: EXPERIMENTAL
Intervention: Primary phacoemulsification and intraocular lens implantation (PPI)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Conventional surgical iridectomy (CSI)
Number of subjects: 43
Study: 10512282

Group type: EXPERIMENTAL
Intervention: Ropivacaine (286 mg, 66 mL)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Saline (66 mL)
Number of subjects: 58
Study: 7593149

Group type: EXPERIMENTAL
Intervention: Troxerutin
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 2177648

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 20 mg/day for 12 days each calendar month for 3 months, then 10 mg/day for a further 3 months
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dydrogesterone 10 mg/day in reverse sequence
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both dydrogesterone doses
Number of subjects: 16
Study: 375858

Group type: EXPERIMENTAL
Intervention: 10-mg troche, five times a day for two weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50-mg troche, five times a day for two weeks
Number of subjects: 0
Study: 30593775

Group type: EXPERIMENTAL
Intervention: CsA CE 0.1% (1 mg/ml) eye drops 4 times daily (high dose)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: CsA CE twice daily (low dose) plus vehicle twice daily
Number of subjects: 169

Group type: COMPARATOR
Intervention: Vehicle 4 times daily
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: High-dose CsA CE
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Low-dose CsA CE
Number of subjects: 169
Study: 27876603

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - 48 Gy in 4 fractions for peripherally located lesions; 60 Gy in 8 fractions for centrally located lesions
Number of subjects: 324

Group type: COMPARATOR
Intervention: Conventionally hypofractionated radiotherapy (CRT) - 60 Gy in 15 fractions
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: SBRT
Number of subjects: 324
Study: 26329614

Group type: EXPERIMENTAL
Intervention: CHAP intervention (community-based program)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0